Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Organisation › Details

Emergex (Group)

Emergex, a UK-based biotechnology company headquartered in Abingdon, UK, is pioneering the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response to address some of the world’s most immediate health threats such as COVID-19, Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections. These set-point vaccines modify the initial immune status of recipients in a way that ‘primes’ their immune systems to recognise subsequent infectious agents much like a natural infection would do, preventing an acute or severe manifestation of the disease. Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines, including using synthetic peptide codes determined on actual infected cells and using a proprietary gold nanoparticle carrier system for programming. The Company has a growing pipeline of vaccine candidates. The most advanced development programme is a vaccine for Dengue Fever, which may also be disease modifying for other Flaviviruses such as the Zika and Yellow Fever viruses. Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine. Emergex has partnered with the Institute of Molecular and Cell Biology (IMCB) of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease and has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. This initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region. *

 

Period Start 2016-01-01 established
Products Industry antibiotic
  Industry 2 virostatic agent
Persons Person Rademacher, Thomas (Emergex 202001 CEO + Co-Founder)
  Person 2 Moore-Thornicroft, Storme (Emergex Vaccines 202011 COO + Co-Founder)
     
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street 4/5 Dunmore Court
Wootton Road
  City OX13 6BH Abingdon, Oxfordshire
  Tel +44 -1235-527589
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Emergex Vaccines Holding Ltd.. (11/18/20). "Press Release: Emergex Vaccines Raises US$11 Million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases". Abingdon.
     
   
Record changed: 2020-11-22

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Emergex (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top